Gemcitabine

FDA Approved: * December 18, 2008
Pharm Company: * SICOR PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Gemcitabine Overview

Gemcitabine, with brand names including Gemzar,[1] is a chemotherapy medication.[2] It treats cancers including testicular cancer,[3] breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer.[2][4] It is administered by intravenous infusion.[2] It acts against neoplastic growth, and it inhibits the replication of Orthohepevirus A, the causative agent of Hepat...

Read more Gemcitabine Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Gemcitabine

Recent Gemcitabine Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Gemcitabine
  • Injection: 100mg/ml, 1g, 1g/26.3ml, 1gm, 1gm/26.3ml (38mg/ml), 1gm/vial, 200mg, 200mg/5.26ml (38mg/ml), 200mg/5.3ml, 200mg/vial, 2g, 2g/52.6ml, 2gm/52.6ml (38mg/ml), 2gm/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Gemcitabine: (83 results)

Showing the first 20, Sorted by National Drug Code
  • 0069-3857 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Pfizer Laboratories Div Pfizer Inc.
  • 0069-3858 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Pfizer Laboratories Div Pfizer Inc.
  • 0069-3859 Gemcitabine Hydrochloride 2 g/50ml Intravenous Injection, Powder, Lyophilized, for Solution by Pfizer Laboratories Div Pfizer Inc.
  • 0143-9394 Gemcitabine 200 mg Intravenous Injection, Powder, Lyophilized, for Solution by Hikma Pharmaceuticals USA Inc.
  • 0143-9395 Gemcitabine 1 g/1 Intravenous Injection, Powder, Lyophilized, for Solution by Hikma Pharmaceuticals USA Inc.
  • 0409-0181 Gemcitabine 38 mg/ml Intravenous Injection, Solution by Hospira, Inc.
  • 0409-0182 Gemcitabine 38 mg/ml Intravenous Injection, Solution by Hospira, Inc.
  • 0409-0183 Gemcitabine 38 mg/ml Intravenous Injection, Solution by Hospira, Inc.
  • 0409-0185 Gemcitabine 38 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Hospira, Inc.
  • 0409-0186 Gemcitabine 38 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Hospira, Inc.
  • 0409-0187 Gemcitabine 38 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Hospira, Inc.
  • 0591-3562 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Watson Laboratories, Inc.
  • 0591-3563 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Watson Laboratories, Inc.
  • 0703-5775 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Teva Parenteral Medicines, Inc.
  • 0703-5778 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Teva Parenteral Medicines, Inc.
  • 0781-3282 Gemcitabine Hcl 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Sandoz Inc
  • 0781-3283 Gemcitabine Hcl 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Sandoz Inc
  • 16714-909 Gemcitabine 200 mg Intravenous Injection, Powder, Lyophilized, for Solution by Northstar Rx LLC
  • 16714-930 Gemcitabine 1 g/1 Intravenous Injection, Powder, Lyophilized, for Solution by Northstar Rx LLC
  • 16729-092 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Accord Healthcare, Inc.
  • 63 more results ...

Other drugs which contain Gemcitabine or a similar ingredient: (3 results)

Related Gemcitabine Topics:

GEMCITABINE/GEMZAK
CHEMOTHERAPY ## What is the dosage of gemcitabin + Mannitol +Sodium Acetate Combination... 1 reply